Medical Tourism in Mexico Led to Deadly Fungal Illness for Americans

Follow Drugslib on

Medically reviewed by Drugs.com.

By Dennis Thompson HealthDay Reporter

FRIDAY, Feb. 9, 2024 -- Medical tourism to Mexico for cosmetic procedures exposed Americans to a deadly fungal infection last year, a new report shows.

An outbreak of Fusarium solani meningitis occurred at two clinics in Matamoros specializing in elective cosmetic procedures like breast augmentation, liposuction and Brazilian butt lifts.

The new report, published Feb. 8 in the New England Journal of Medicine, tracked the progress of 13 hospitalized patients exposed to the F. solani fungus through epidural anesthesia administered by the River Side Surgical Center and Clinica K-3 between Jan. 1 and May 13, 2023.

Nine of the 13 patients died from injury to arteries feeding their brainstem, brain and spinal cord, said lead researcher Dr. Nora Strong, a postdoctoral fellow in infectious diseases at the University of Texas Health Science Center in Houston.

“The outbreak of this severe mold infection affected primarily young, otherwise healthy people as result of medical tourism,” Strong said in a university news release. “Patients from Mexico and the U.S. experienced severe, and ultimately mortal, neurologic and vascular injuries as a result of the infection.”

Epidural anesthesia directly injected F. solani fungus into the patient’s cerebrospinal fluid, which can cause severe meningitis in otherwise healthy people, the report noted.

“Over time, multiple patients experienced the narrowing of important blood vessels in their brains, leading to stroke or severe hemorrhages that eventually led to death in many of the patients,” Strong said.

Three of the four surviving patients remain on an experimental antifungal treatment for invasive mold infections, the researchers said.

One patient who remains on therapy has experienced a state of diminished motivation following a bleed into the space surrounding their brain, results show. The other three survivors escaped with no long-term thinking, sensory or motor deficits from their infection.

Nearly all patients were treated with systemic antifungal therapy, which initially improved their condition.

However, this standard therapy eventually failed and rapid fungal regrowth occurred in the patient’s spinal fluid.

“Eventually, we learned through advanced molecular and microbiological techniques that the fungus was resistant to all antifungal agents, except the experimental drug Fosmanogepix,” said senior researcher Dr. Luis Ostrosky-Zeichner, division director of infectious diseases at the University of Texas Health Science Center.

“Using that, along with state-of-the-art neurosurgical and endovascular techniques, changed the course of the outbreak,” Ostrosky-Zeichner added.

Sources

  • University of Texas, news release, Feb. 7, 2024

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2024-02-09 22:15

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords